Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYTHIC: Lunresertib Alone or in Combination With RP-3500 or Zedoresertib in Advanced Solid Tumors
NCT04855656Phase 1Recruiting
- Sponsor
- Debiopharm
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of lunresertib in solid tumor (3 arms), sponsored by Debiopharm. Primary endpoints: Safety and Tolerability of lunresertib at 90 days, Maximum Tolerated Dose at 90 days and 2 more. Started Apr 2021; status: recruiting.
02
Drugs
lunresertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04855656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855656.